小程序掃碼下單
本網站銷售的所有產品僅用于工業應用或者科學研究等非醫療目的，不可用于人類或動物的臨床診斷或者治療，非藥用，非食用。
利妥昔單抗
英文名：Rituximab
Cas號：174722-31-7
Cas號：174722-31-7
檢測信息查詢
| 貨號 | 規格 | 貨期 | 庫存 | 價格 | 促銷價 | 訂購 |
| 13081324832-1mg | 97% 12mg/ml | 2-3天 | 0 | ￥1495 | ||
| 13081324832-5mg | 97% 12mg/ml | 2-3天 | 0 | ￥3995 | ||
| 13081324831-1mg | 99.85% | 0 | ￥5600 | |||
| 13081324831-5mg | 99.85% | 0 | ￥11200 |
| 別 名 | 美羅華;美羅華(利妥昔單抗) |
| Cas號 | 174722-31-7 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產品參數 | Description
Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer. Molecular Weight 144544.44 Shipping Shipping with dry ice. Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50. [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54. [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43. |
| 性狀 | Rituximab是用于治療某些自身免疫疾病和癌癥類型的抗CD20嵌合單克隆抗體。 |
| 貯存 |
滬公網安備 31012002003054號